The re-dose of ISP-001 has been well-tolerated, to date, and Immusoft continues to observe positive results SAN FRANCISCO, Oct. 7, 2025 /PRNewswire/ — Immusoft of CA, a clinical stage, engineered B cell company, today announced a historic achievement: the safe and well-tolerated re-dosing of a…

Safety and initial activity of autologous human B cells engineered to express the enzyme iduronidase. Results from a first-in-human clinical trial in subjects with MPS I SAN FRANCISCO, May 13, 2025 /PRNewswire/ — Immusoft of CA, a cell therapy company dedicated to improving the lives…

Safety and initial activity of autologous human B cells genetically engineered to express human iduronidase using the Sleeping Beauty transposon system. Results from a first-in-human clinical trial in subjects with MPS I SAN FRANCISCO, Jan. 27, 2025 /PRNewswire/ — Immusoft of CA, a cell therapy…

First-in-human clinical trial of genetically engineered B cells: Application to the treatment of mucopolysaccharidosis type I